Commit Biologics Secures €5.5M in Extension to Seed Financing

  • Commit Biologics has raised an additional €5.5 million, bringing its total seed funding to €21.5 million.
  • The funding will support the development of Commit’s BiCE platform, which aims to target cancer and autoimmune diseases through complement system activation.

Commit Biologics, a company focused on treating cancer and autoimmune diseases by activating the complement system, has secured €5.5 million in additional seed funding. This new investment brings its total seed financing to €21.5 million. The round was led by Korys, with participation from existing investors Novo Holdings and Bioqube Ventures.

The funds will be used to advance Commit’s Bispecific Complement Engaging (BiCE™) platform, which targets the complement protein C1q to activate the immune system and selectively destroy tumor or autoimmune cells. This financing extends the company’s runway into late 2026.

Commit has also appointed Mikkel Wandahl Pedersen, its Chief Scientific Officer, as Interim CEO. Dr. Pedersen brings over 20 years of experience in immuno-oncology and autoimmune disease research. He previously served as CSO of Nykode Therapeutics and Symphogen.

Dr. Pedersen commented, “This additional financing from Korys underscores the great potential of our BiCE platform to redefine the treatment of cancer and autoimmune diseases.” He also emphasized the importance of the extended funding in enabling further development of the platform.

Eva Van Overmeire, Senior Investment Manager at Korys, expressed confidence in Commit’s innovative approach, stating, “We are impressed with the progress made by the Commit team… and we are confident they have the expertise to drive the platform forward.”

Sign up to the free weekly newsletter for all the latest biotech news, resources and podcasts.  Register here

Experience the future of contract manufacturing

Join us at CDMO Live, 7-8 May 2025 in Rotterdam for an exclusive live event dedicated to contract manufacturing partnerships. Apply for your ticket.

UPCOMING EVENT

New from PharmaSource, CDMO Live (Rotterdam, May 7-8, 2025) brings together biopharma’s manufacturing leaders to optimise their outsourcing strategy.

Who do you rate?
Recommend a Supplier

Help us find the most innovative and trusted suppliers in Pharma and Biotech.